Medicure (CVE:MPH) Trading Down 1.1%

Medicure Inc. (CVE:MPH) shares fell 1.1% during mid-day trading on Monday . The company traded as low as C$4.50 and last traded at C$4.50, 201 shares were traded during mid-day trading. A decline of 97% from the average session volume of 8,009 shares. The stock had previously closed at C$4.55.

The stock’s 50-day moving average is C$4.49 and its 200-day moving average is C$5.29. The stock has a market cap of $67.66 million and a P/E ratio of -25.57. The company has a current ratio of 4.71, a quick ratio of 4.11 and a debt-to-equity ratio of 0.70.

Medicure (CVE:MPH) last announced its earnings results on Thursday, August 8th. The company reported C($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of C($0.10) by C$0.04. The company had revenue of C$6.30 million during the quarter, compared to the consensus estimate of C$5.60 million. On average, equities analysts forecast that Medicure Inc. will post 0.22 EPS for the current year.

About Medicure (CVE:MPH)

Medicure Inc, a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome.

Featured Story: Economic Reports

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with's FREE daily email newsletter.